Einzeltreffer — DigiBib

The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.

Titel:	Tumor vascular marker-targeted vaccines
Autor/in / Beteiligte Person:	Coukos, George ; Facciabene, Andrea
Link:	View record in USPTO Patent Grants (Volltext)
Veröffentlichung:	2016
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Grants Sprachen: English Patent Number: 9,290,556 Publication Date: March 22, 2016 Appl. No: 13/121638 Application Filed: September 29, 2009 Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, PA, US) Claim: 1. A vaccine comprising a nucleic acid construct comprising a nucleic acid sequence encoding a tumor endothelial marker (TEM)-1 protein or immunogenic fragment thereof fused in frame to a nucleic acid sequence encoding the N-terminal domain of fragment C of tetanus toxoid (DOM). Claim: 2. The vaccine of claim 1 , wherein said vaccine is a DNA vaccine or a recombinant viral vaccine. Claim: 3. The vaccine of claim 1 , wherein said vaccine additionally comprises one or more tumor associated antigens. Claim: 4. A method of immunizing a subject against a tumor, comprising administering to said subject the vaccine according to claim 1 . Claim: 5. The method of claim 4 , wherein said tumor is selected from the group consisting of an ovarian tumor, a renal tumor and a breast tumor. Patent References Cited: 2004/0005563 January 2004 Mack et al. ; 2004/0009154 January 2004 Khan et al. ; 2005/0142138 June 2005 St. Croix et al. ; 2006/0286074 December 2006 Tang et al. ; 2007/0154928 July 2007 Mack et al. ; 2008/0181896 July 2008 Khan et al. ; WO 02/083874 October 2002 ; WO 02/086443 October 2002 ; WO 03/042661 May 2003 ; WO 2005/077977 August 2005 ; WO 2006/017759 February 2006 ; WO 2007/042169 April 2007 ; WO 2008/105978 September 2008 Other References: Buckanovich et al., “Tumor Vascular Proteins As Biomarkers in Ovarian Cancer” J. of Clinical Oncology, vol. 25, No. 7, pp. 852-861. cited by applicant ; Neri et al., “Tumour Vascular Targeting”, Nature Reviews 5: 436-446, 2005. cited by applicant ; Nanda et al., “Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors”, PNAS, vol. 103, No. 9, 2006, pp. 3351-3356. cited by applicant Primary Examiner: Halvorson, Mark Attorney, Agent or Firm: Cohen, Mark S. ; Pearl Cohen Zedek Latzer Baratz LLP

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Tumor vascular marker-targeted vaccines